Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$80.52 USD

80.52
730,938

+0.75 (0.94%)

Updated May 30, 2024 04:00 PM ET

After-Market: $80.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?

by Zacks Equity Research

Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility

by Zacks Equity Research

Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.

Shaun Pruitt headshot

3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List

by Shaun Pruitt

Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Lantheus Holdings (LNTH) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock

by Zacks Equity Research

Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research

Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.

Lantheus Holdings (LNTH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Lantheus Holdings (LNTH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.

Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today

by Zacks Equity Research

The latest trading day saw Lantheus Holdings (LNTH) settling at $65.56, representing a +0.55% change from its previous close.

Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings

by Zacks Equity Research

Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) reachead $65.21 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

by Zacks Equity Research

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is Lantheus (LNTH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.